A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.
I agree biomedeng...it does seem that the trials are quite promising and I would rate chances of approval as being very good. This caught my eye last year in a Fool article and after some DD I put real money in it with the expectation that it would be more or less "dead" money until approval which is slated for late this year (2008). From there the CABG trials can send it to another level along with partnerships Dyax is currently courting. I suspect that we will get a better idea of that scenario in the next CC. Do you have any skin in this game?